Clinical Report: Roswell Park Set to Open Several New Trials for Innovative CAR T-Cell Therapies

Overview

Roswell Park Comprehensive Cancer Center is launching several innovative CAR T-cell therapy trials in 2025, targeting various malignancies. Notably, these include a phase 1 trial for B-cell malignancies with a customized CAR design aimed at enhancing T-cell persistence.

Background

CAR T-cell therapies represent a significant advancement in cancer treatment, particularly for hematologic malignancies. The development of new trials at Roswell Park highlights the ongoing need for effective therapies, especially for patients who have relapsed after standard treatments. Innovative approaches, such as customized signaling domains in CAR T-cells, may improve patient outcomes and expand treatment options.

Data Highlights

No numerical data available in the source material.

Key Findings

• New CAR T-cell trials at Roswell Park include treatments for B-cell malignancies and solid tumors.
• A phase 1 trial will investigate CAR T-cells targeting the CD19 antigen, designed to resist exhaustion.
• Another trial will target the CD3 antigen for acute myeloid leukemia (AML) patients who have relapsed.
• Innovative CAR T-cells will be engineered to express cytokines to combat hostile tumor microenvironments.
• These trials are first-in-human studies, emphasizing the novel approaches being explored at Roswell Park.

Clinical Implications

The upcoming trials at Roswell Park may provide new treatment options for patients with limited alternatives, particularly those who have relapsed after previous therapies. The focus on enhancing T-cell persistence and resilience against tumor microenvironments could lead to improved outcomes in challenging cancer cases.

Conclusion

The innovative CAR T-cell trials set to open at Roswell Park represent a promising advancement in cancer therapy. These efforts may significantly impact treatment paradigms for patients with relapsed or refractory malignancies.

References

1. Roswell Park Comprehensive Cancer Center, Roswell Park Accelerates CAR T-Cell Innovation with Upcoming Trials, 2023 -- Overview of CAR T-cell trials
2. Roswell Park Comprehensive Cancer Center, Roswell Park Offering CAR T Trial for Autoimmune Conditions, 2023 -- CAR T trials for autoimmune diseases
3. Roswell Park Comprehensive Cancer Center, Roswell Park Researchers Present New Approach to Understanding Challenging CAR T-Cell Toxicities, 2023 -- Research on CAR T-cell toxicities
4. Roswell Park Comprehensive Cancer Center, New CAR T-Cell Therapy Shows Promise as ‘Magic Bullet’ for Patients with Relapsed/Refractory AML, 2023 -- CAR T-cell therapy for AML
5. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations, Bone Marrow Transplantation, 2025 -- EBMT guidelines on CAR T-cell therapy
6. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations | Bone Marrow Transplantation
7. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume - PMC